Research Articles
From Dialysis to Cure: How New Antivirals Are Revolutionizing Hepatitis C Treatment in Kidney Patients
Explore how direct-acting antivirals (DAAs) are transforming hepatitis C treatment for patients with chronic kidney disease, achieving cure rates exceeding 95% even in end-stage renal disease.
The 8-Week Revolution: Short-Duration Antivirals Transform Care for Cancer Patients with Hepatitis C
Breakthrough research shows 8-week DAA therapy achieves 100% cure rates in HCV-infected cancer patients, enabling faster oncology treatment without delays.